Global Risk Management in Patients with Type 2 Diabetes Mellitus

American Journal of Cardiology

Volumn 99, Issue 4 SUPPL., 2007, Pages 41-50

  Davidson, Michael H ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; APOLIPOPROTEIN B; ATORVASTATIN; BEZAFIBRATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EXENDIN 4; FENOFIBRATE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN; METFORMIN; NICOTINIC ACID; PIOGLITAZONE; PLACEBO; PRAMLINTIDE; PRAVASTATIN; RAMIPRIL; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; SULFONYLUREA DERIVATIVE; TIROFIBAN; TORCETRAPIB; TRIACYLGLYCEROL;

ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG FATALITY; DRUG MEGADOSE; EDEMA; FLUID RETENTION; GASTROINTESTINAL TOXICITY; GLUCOSE BLOOD LEVEL; HEART FAILURE; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOGLYCEMIA; LIFESTYLE MODIFICATION; LIPOPROTEIN BLOOD LEVEL; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; SIDE EFFECT; WEIGHT GAIN;

ALGORITHMS; APOLIPOPROTEINS B; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; PEPTIDE FRAGMENTS; RISK FACTORS;

EID: 33846977402     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.11.005     Document Type: Article

References (52)

1. American Diabetes Association. Clinical practice recommendations 2006. Diabetes Care 29 suppl (2006) S1-S77
2. ACE/AACE Diabetes Recommendations Implementation Writing Committee, Lebovitz H.E., Austin M.M., Blonde L., Davidson J.A., Del Prato S., Gavin III J.R., Handelsman Y., Jellinger P.S., Levy P., Riddle M.C., Roberts V.L., and Siminerio L.M. ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations. Endocr Pract 12 suppl (2006) 6-12
3. In: Snow V. (Ed). Clinical Practice: American College of Physicians and US Preventive Services Task Force Recommendations (2005), American College of Physicians, Philadelphia
4. Cifkowa R., Erdine S., Fagard R., Farsang C., Haaegerty A.M., Kiowski W., Kjeldsen S., Luscher T., Mallion J.M., Mancia G., et al., ESH/ESC Hypertension Guidelines Committee. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens 21 (2003) 1779-1786
5. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith Jr. S.C., Stone N.J., National Heart, Lung, and Blood Institute, the American College of Cardiology Foundation, and and American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
6. International Diabetes Federation, Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Available at: http://www.idf.org/home/index.cfm?node=1457. Accessed September 12, 2006.
7. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., Jones D.W., Materson B.J., Oparil S., Wright Jr. J.T., Roccella E.J., National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (2003) 2560-2572
8. Genest J., Frohlich J., Fodor G., McPherson R., and Working Group on Hypercholesterolemia and Other Dyslipidemias. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ 169 (2003) 921-924
9. Wood D., Wray R., Poulter N., Williams B., Kirby M., Patel V., Durrington P., Reckless J., Davis M., and Sivers F. JBS2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 91 suppl (2005) v1-v52
10. Helaine R.E., Foster G.L., Bardsley J., and Ratner R.E. Achievement of American Diabetes Association clinical practice recommendations among US adults with diabetes 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care 29 (2006) 531-537
11. Saydah S.H., Fradkin J., and Cowie C.C. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291 (2004) 335-342
12. Harris S.B., Ekoe J.M., Zdamowicz Y., and Webster-Bogaert S. Glycemic control and morbidity in the Canadian primary care setting (results of the diabetes in Canada evaluation study). Diabetes Res Clin Pract 70 (2005) 90-97
13. Davidson M.H., Maki K.C., Pearson T.A., Pasternak R.C., Deedwania P.C., McKenney J.M., Fonarow G.C., Maron D.J., Ansell B.J., Clark L.T., and Ballantyne C.M. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 96 (2005) 556-563
14. Smith Jr. S.C., Allen J., Blair S.N., Bonow R.O., Brass L.M., Fonarow G.C., Grundy S.M., Hiratzka L., Jones D., Krumholz H.M., et al., American Heart Association/American College of Cardiology, and the National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Endorsed by the National Heart, Lung, and Blood Institute. Circulation 113 (2006) 2363-2372
15. Collins R., Armitage J., Parish S., Sleigh P., and Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes; a randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
16. Waters D.D., Guyton J.R., Herrington D.M., McGown M.P., Wenger N.K., Shear C., and TNT Steering Committee Members and Investigators. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?. Am J Cardiol 93 (2004) 154-158
17. Pedersen T.R., Faergeman O., Kastelein J.P., Olsson A.G., Tikkanen M.J., Holme I., Larsen M.L., Bendiksen F.S., Lindahl C., Szarek M., Tsai J., and Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. JAMA 294 (2005) 2437-2445
18. Davidson M.H. Reducing residual risk for patients on statin therapy: the potential role of combination therapy. Am J Cardiol 96 suppl (2005) 3K-13K
19. Clearfield M., Downs J.R., Lee M., Langendorfer A., McConathy W., and Gotto Jr. A.M. Implications from the Air Force/Texas Coronary Atherosclerosis Prevention Study for the Adult Treatment Panel III guidelines. Am J Cardiol 96 (2005) 1674-1680
20. Sattar N., Gaw A., Scherbakova O., Ford I., O'Reilly D.S., Haffner S.M., Isles C., Macfarlane P.W., Packard C.J., Cobbe S.M., and Shepherd J. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108 (2003) 414-419
21. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., Skene A.M., Tan M.H., Lefebvre P.J., Murray G.D., et al., PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
22. Scott R., Best J., Forder P., Taskinen M.R., Simes J., Barter P., Keech A., and FIELD Study Investigators. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, a randomized, placebo-controlled trial: baseline characteristics and short-term effects of fenofibrate. Cardiovasc Diabetol 4 (2005) 13
23. Knopp R.H., d'Emden M., Smilde J.G., Pocock S.J., and ASPEN Study Group. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes. Diabetes Care 29 (2006) 1478-1485
24. Goldberg R.B., Kendall D.M., Deeg M.A., Buse J.B., Zagar A.J., Pinaire J.A., Tan M.H., Khan M.A., Perez A.T., Jacober S.J., and GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28 (2005) 1547-1554
25. Hsueh W.A., and Law R.E. PPARγ and atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Biol 21 (2001) 1891-1895
26. Tenenbaum A., Motro M., Fisman E.Z., Tanne D., Boyko V., and Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 165 (2005) 1154-1160
27. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., Faas F.H., Linares E., Schaefer E.J., Schectman G., Wilt T.J., Wittes J., and Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341 (1999) 410-418
28. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., Thomason M.J., Mackness M.I., Charlton-Menys V., Fuller J.H., and CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
29. Gaede P., Vedel P., Larson N., Jensen G.V., Parving H.H., and Pederson O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003) 383-393
30. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., Skene A.M., and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
31. de Lemos J.A., Blazing M.A., Wiviott S.D., Lewis E.F., Fox K.A., White H.D., Rouleau J.L., Pedersen T.R., Gardner L.H., Mukherjee R., et al., A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292 (2004) 1307-1316
32. Davidson M.H. Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. Expert Opin Drug Saf 3 (2004) 547-557
33. Davidson M.H., Bays H.E., Stein E., Maki K.C., Shalwitz R.A., Doyle R., and TRIMS Investigators. Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects. Clin Cardiol 29 (2006) 268-273
34. Tenebaum A., Motro M., Fisman E.Z., Tanne D., Boyko V., and Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 165 (2005) 2431-2432
35. Action to Control Cardiovascular Risk in Diabetes (ACCORD). ACCORD website. Available at: http://www.accord.cardio.on.ca/Index_E.html. Accessed August 10, 2006.
36. Brookes L. Phase 2 studies with torcetrapib/atorvastatin combination. Available at: http://www.medscape.com/viewarticle/518571l. Accessed August 10, 2006.
37. AACE Hypertension Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of hypertension. Endocr Pract 12 (2006) 193-222
38. Nathan D.M., Buse J.B., Davidson M.B., Heine R.J., Holman R.R., Sherwin R., and Zinman B. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29 (2006) 1963-1972
39. Goldberg R.B., Kendall D.M., Deeg M.A., Buse J.B., Zagar A.J., Pinaire J.A., Tan M.H., Khan M.A., Perez A.T., Jacober S.J., and GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia: response to Bell and Brunzell. Diabetes Care 28 (2005) 2985-2986
40. Szapary P.O., Bloedon L.T., Samaha F.F., Duffy D., Wolfe M.L., Soffer D., Reilly M.P., Chittams M.J., and Rader D.J. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol 26 (2006) 182-188
41. US National Institutes of Health. A study of pioglitazone HCl versus glimepiride in subjects with type 2 diabetes measuring the progression of atherosclerosis (CHICAGO). Available at: http://www.clinicaltrials.gov/ct/show/NCT00225264?order=1. Accessed August 10, 2006.
42. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368 (2006) 1096-1105
43. Meier J.J., and Nauck M.A. Incretins and the development of type 2 diabetes. Curr Diab Rep 6 (2005) 194-201
44. Stein E.A., Sniderman A., and Laskarzewski P. Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B. Am J Cardiol 96 suppl (2005) 36K-43K
45. Gotto Jr. A.M., Whitney E., Stein E.A., Shapiro D.R., Clearfield M., Weis S., Jou J.Y., Langendorfer A., Beere P.A., Watson D.J., Downs J.R., and de Cani J.S. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 101 (2000) 477-484
46. Grundy S.M. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 106 (2002) 2537-2542
47. Walldius G., Jungner I., Aastveit A.H., Holme I., Furgerg C.D., and Sniderman A.D. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 42 (2004) 1355-1356
48. HDL). Clin Biochem 34 (2001) 583-588
49. Tan M.H., Johns D., and Glazer N.B. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. Clin Chem 50 (2004) 1184-1188
50. Ridker P.M., Buring J.E., Shih J., Matias M., and Hennekens C.H. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98 (1998) 731-733
51. Ridker P.M., Morrow D.A., Rose L.M., Rifai N., Cannon C.P., and Braunwald E. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol 45 (2005) 1644-1648
52. O'Donoghue M., Morrow D.A., Sabatine M.S., Murphy S.A., McCabe C.H., Cannon C.P., and Braunwald E. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction) trial. Circulation 113 (2006) 1745-1752